The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes
Abstract
Objective : Low levels of testosterone in men have been shown to be associated with type 2 diabetes, visceral adiposity, dyslipidaemia and metabolic syndrome. We investigated the effect of testosterone treatment on insulin resistance and glycaemic control in hypogonadal men with type 2 diabetes. Design : This was a double-blind placebo-controlled crossover study in 24 hypogonadal men (10 treated with insulin) over the age of 30 years with type 2 diabetes. Methods : Patients were treated with i.m. testosterone 200 mg every 2 weeks or placebo for 3 months in random order, followed by a washout period of 1 month before the alternate treatment phase. The primary outcomes were changes in fasting insulin sensitivity (as measured by homeostatic model index (HOMA) in those not on insulin), fasting blood glucose and glycated haemoglobin. The secondary outcomes were changes in body composition, fasting lipids and blood pressure. Statistical analysis was performed on the delta values, with the treatment effect of placebo compared against the treatment effect of testosterone. Results : Testosterone therapy reduced the HOMA index (−1.73 ± 0.67, P = 0.02, n = 14), indicating an improved fasting insulin sensitivity. Glycated haemoglobin was also reduced (−0.37 ± 0.17%, P = 0.03), as was the fasting blood glucose (−1.58 ± 0.68 mmol/l, P = 0.03). Testosterone treatment resulted in a reduction in visceral adiposity as assessed by waist circumference (−1.63 ± 0.71 cm, P = 0.03) and waist/hip ratio (−0.03 ± 0.01, P = 0.01). Total cholesterol decreased with testosterone therapy (−0.4 ± 0.17 mmol/l, P = 0.03) but no effect on blood pressure was observed. Conclusions : Testosterone replacement therapy reduces insulin resistance and improves glycaemic control in hypogonadal men with type 2 diabetes. Improvements in glycaemic control, insulin resistance, cholesterol and visceral adiposity together represent an overall reduction in cardiovascular risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3–12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“and a decrease in the waist hip ratio after 3 months (31, 36) or after 6 months and 30 weeks respectively (17).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“A decrease in trunk fat or waist circumference was noted in a number of studies after 3 months (35, 36) with continuous decline over 24 months (32)”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“Several studies indicate that upon testosterone administration, serum glucose is reduced after 3 months in men with impaired glucose tolerance (31, 36, 43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“A decline in HbA1c was observed after 3 months (31, 36, 43) with further decrease after 12 months (43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“A decrease in serum proinsulin and insulin was noted after 3 months (43) or 6 months (45), and a decrease in homeostasis model assessment index of insulin resistance (HOMA-IR) after 3 months (36) or 6 months (45–47).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“Certainly, testosterone replacement can improve performance, mood, and libido in men with hypogonadism (22) and augments insulin sensitivity (11,15).”
From Low testosterone levels are common and associated with insulin resistance in men with diabetes (2008) · cites this paper as [11]
In the citing paper
“T plays an important role in maintaining glycemic control [2].”
In the citing paper
“Furthermore, there is recent evidence that testosterone replacement therapy improves insulin resistance, glycemic control, cholesterol levels, and waist circumference in diabetic men with low testosterone levels (26).”
From Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes (2007) · cites this paper as [26]
In the citing paper
“Testosterone treatment has also been shown to reduce insulin resistance in obese men (23,24), men with heart failure (25), and type 2 diabetic subjects (26).”
From Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes (2007) · cites this paper as [26]
In the citing paper
“Two studies in type 2 diabetic men have shown an improvement in glycemic control (26,27) with testosterone replacement therapy”
From Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes (2007) · cites this paper as [26]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Malkin, C. J., Pugh, P. J., Jones, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031069 · Cited by 731
Self-citationThe assessment of insulin resistance in man
Wallace, T. M., & Matthews, D. R. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00745.x · Cited by 685
Validation of a screening questionnaire for androgen deficiency in aging males
Morley, J. E., Charlton, E., Patrick, P., Kaiser, F. E., Cadeau, P., McCready, D., & Perry, H. M. (2000) · Metabolism · doi:10.1053/meta.2000.8625 · Cited by 662
(1996) · PubMed · Cited by 643
Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631
Stellato, R. K., Feldman, H. A., Hamdy, O., Horton, E. S., & McKinlay, J. B. (2000) · Diabetes Care · doi:10.2337/diacare.23.4.490 · Cited by 618
Oh, J.-Y., Barrett-Connor, E., Wedick, N. M., & Wingard, D. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.55 · Cited by 594
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 785
The complex association between metabolic syndrome and male hypogonadism
Dimopoulou, C., Goulis, D. G., Corona, G., & Maggi, M. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.024 · Cited by 66
The role of testosterone in type 2 diabetes and metabolic syndrome in men
Saad, F. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000800002 · Cited by 64
Testosterone a key factor in gender related metabolic syndrome
Bianchi, V. E., & Locatelli, V. (2018) · Obesity Reviews · doi:10.1111/obr.12633 · Cited by 65
Low testosterone and anaemia in men with type 2 diabetes
Grossmann, M., Panagiotopolous, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., Jerums, G., & Thomas, M. C. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03357.x · Cited by 60
Testosterone treatment in the aging male: myth or reality?
Nigro, N., & Christ‐Crain, M. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13539 · Cited by 59
Schwartz, E., & Holtorf, K. (2008) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.07.015 · Cited by 59
Kapoor, D., Channer, K. S., & Jones, T. H. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.022 · Cited by 58
Self-citationPromising role of medicinal plants in the regulation and management of male erectile dysfunction
Masuku, N. P., Unuofin, J. O., & Lebelo, S. L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110555 · Cited by 58
Traish, A. M., & Zitzmann, M. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9323-2 · Cited by 57
Testosterone Deficiency: A Review and Comparison of Current Guidelines
Kwong, J. C. C., Krakowsky, Y., & Grober, E. D. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.03.262 · Cited by 58
Li, S., Zhao, Y., Yang, Y., Wang, X., Nie, M., Wu, X., Mao, J., & Veglio, F. (2020) · International Journal of Endocrinology · doi:10.1155/2020/4732021 · Cited by 57
Diabetes Status and Association With Risk of Tuberculosis Among Korean Adults
Yoo, J. E., Kim, D., Han, K., Rhee, S. Y., Shin, D. W., & Lee, H. J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.26099 · Cited by 55
Brand, J. S., Wareham, N. J., Dowsett, M., Folkerd, E. J., van der Schouw, Y. T., Luben, R., & Khaw, K. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03951.x · Cited by 55
Auriemma, R. S., Galdiero, M., Vitale, P., Granieri, L., Calzo, F. L., Salzano, C., Ferreri, L., Pivonello, C., Cariati, F., Coppola, G., et al. (2015) · Neuroendocrinology · doi:10.1159/000371851 · Cited by 55
El-Twab, S. M. A., Mohamed, H. M., & Mahmoud, A. M. (2016) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0503 · Cited by 54
Effects of testosterone replacement and its pharmacogenetics on physical performance and metabolism
Zitzmann, M. (2008) · Asian Journal of Andrology · doi:10.1111/j.1745-7262.2008.00405.x · Cited by 53
Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men.
Cattabiani, C., Basaria, S. S., Ceda, G. P., Luci, M., Vignali, A., Lauretani, F., Valenti, G., Volpi, R., & Maggio, M. G. (2012) · PubMed · doi:10.3275/8061 · Cited by 52
Vicencio, J. M., Estrada, M., Galvis, D. M. S., Bravo, R., Contreras‐Ferrat, A. E., Rotter, D., Szabadkai, G., Hill, J. A., Rothermel, B. A., Jaimovich, E., et al. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711795445880 · Cited by 52
Effect of Isopropyl Myristate on Transdermal Permeation of Testosterone From Carbopol Gel
Zidan, A. S., Kamal, N. S., Alayoubi, A. Y., Seggel, M. R., Ibrahim, S. A., Rahman, Z., Cruz, C. N., & Ashraf, M. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.03.016 · Cited by 52
Androgen Deficiency as a Predictor of Metabolic Syndrome in Aging Men
Kapoor, D., & Jones, T. H. (2008) · Drugs & Aging · doi:10.2165/00002512-200825050-00001 · Cited by 52
Self-citationFarias, J. M., Tinetti, M., Khoury, M. C., & Umpierrez, G. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2585 · Cited by 51
Adverse health effects of testosterone deficiency (TD) in men
Traish, A. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.010 · Cited by 51
Tan, W. S., Low, W. Y., Ng, C. J., Tan, W. K., Tong, S. F., Ho, C. C. K., Khoo, E. M., Lee, G., Lee, B. C., Lee, V., et al. (2013) · British Journal of Urology · doi:10.1111/bju.12037 · Cited by 51
Permpongkosol, S., Khupulsup, K., Leelaphiwat, S., Pavavattananusorn, S., Thongpradit, S., & Petchthong, T. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.06.003 · Cited by 51
Testosterone, cardiomyopathies, and heart failure
Diaconu, R., Donoiu, I., Mirea, O., & Bălşeanu, T. A. (2021) · Asian Journal of Andrology · doi:10.4103/aja.aja_80_20 · Cited by 51
The Emerging Link Between Hypogonadism and Metabolic Syndrome
Guay, A. T. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.006015 · Cited by 50
Testosterone Deficiency as One of the Major Endocrine Disorders in Chronic Kidney Disease
Romejko, K., Rymarz, A., Sadownik, H., & Niemczyk, S. (2022) · Nutrients · doi:10.3390/nu14163438 · Cited by 52
Sakr, H. F., Sirasanagandla, S. R., Das, S., Bima, A. I. H., & Elsamanoudy, A. Z. (2023) · Biomedicines · doi:10.3390/biomedicines11082271 · Cited by 52
Stanworth, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.03969.x · Cited by 50
Self-citationGlycemic control and prostate cancer progression: Results from the SEARCH database
Kim, H. S., Presti, J. C., Aronson, W. J., Terris, M. K., Kane, C. J., Amling, C. L., & Freedland, S. J. (2010) · The Prostate · doi:10.1002/pros.21189 · Cited by 49
Biochemical hypogonadism in men with type 2 diabetes in primary care practice
Hackett, G. I., Cole, N., Deshpande, A. A., Popple, M. D., Kennedy, D., & Wilkinson, P. R. (2009) · The British Journal of Diabetes · doi:10.1177/1474651409342635 · Cited by 49
Traish, A. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_22 · Cited by 50
Maseroli, E., Comeglio, P., Corno, C., Cellai, I., Filippi, S., Mello, T., Galli, A., Rapizzi, E., Presenti, L., Truglia, M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01381-8 · Cited by 49
Hypogonadotropic Hypogonadism in Men with Type 2 Diabetes
Dandona, P., Dhindsa, S., Chandel, A., & Chaudhuri, A. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.2001 · Cited by 47
The 20-Year Public Health Impact and Direct Cost of Testosterone Deficiency in U.S. Men
Moskovic, D. J., de Araújo, A. B., Lipshultz, L. I., & Khera, M. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02944.x · Cited by 47
An update on male hypogonadism therapy
Surampudi, P. N., Swerdloff, R. S., & Wang, C. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.913022 · Cited by 46
Sullivan, S. D., Nash, M. S., Tefera, E. A., Tinsley, E. A., Blackman, M. R., & Groah, S. L. (2016) · PM&R · doi:10.1016/j.pmrj.2016.11.005 · Cited by 46
Insulinooporność w chorobach endokrynnych — sposoby terapii
Rogowicz‐Frontczak, A., Majchrzak, A., & Zozulińska‐Ziółkiewicz, D. (2017) · Endokrynologia Polska · doi:10.5603/ep.2017.0026 · Cited by 46
The association between serum testosterone and insulin resistance: a longitudinal study
Ottarsdottir, K., Nilsson, A. G., Hellgren, M. I., Lindblad, U., & Daka, B. (2018) · Endocrine Connections · doi:10.1530/ec-18-0480 · Cited by 51
Determination of steroid hormones in human plasma by GC–triple quadrupole MS
Matysik, S., & Schmitz, G. (2015) · Steroids · doi:10.1016/j.steroids.2015.01.016 · Cited by 45
Benefits and Health Implications of Testosterone Therapy in Men With Testosterone Deficiency
Traish, A. M. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.10.001 · Cited by 46
Secondary male hypogonadism: A prevalent but overlooked comorbidity of obesity
Fernandez-Garcia, J.-C., Molina‐Vega, M., Muñoz-Garach, A., Damas-Fuentes, M., & Tinahones, F. J. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_44_18 · Cited by 49
The Role of testosterone treatment in patients with metabolic disorders
Corona, G., Rastrelli, G., Vignozzi, L., Barbonetti, A., Sforza, A., Mannucci, E., & Maggi, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1938548 · Cited by 46
Knoblovits, P., Costanzo, P., Valzacchi, G. R., Gueglio, G., Layus, A. O., Kozak, A. E., Balzaretti, M., & Litwak, L. (2010) · Journal of Andrology · doi:10.2164/jandrol.109.007757 · Cited by 44
George, A., & Henkel, R. (2014) · Andrologia · doi:10.1111/and.12214 · Cited by 44
Testosterone and heart failure
Volterrani, M., Rosano, G. M. C., & Iellamo, F. (2012) · Endocrine · doi:10.1007/s12020-012-9725-9 · Cited by 44
Dehydroepiandrosterone reduces preadipocyte proliferation via androgen receptor
Fujioka, K., Kajita, K., Wu, Z., Hanamoto, T., Ikeda, T., Mori, I., Okada, H., Yamauchi, M., Uno, Y., Morita, H., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00112.2011 · Cited by 43
Alemany, M. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00027 · Cited by 45
Karolczak, K., Konieczna, L., Kostka, T., Witas, P. J., Sołtysik, B. K., Bączek, T., & Watała, C. W. (2018) · Aging · doi:10.18632/aging.101438 · Cited by 43
Testosterone in Chronic Heart Failure
Malkin, C. J., Jones, T. H., & Channer, K. S. (2008) · Frontiers of hormone research · doi:10.1159/000176053 · Cited by 43
Self-citationGoto, A., Morita, A., Goto, M., Sasaki, S., Miyachi, M., Aiba, N., Terauchi, Y., Noda, M., Watanabe, S., & the Saku Cohort Study Group (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-130 · Cited by 43
Obesity, Body Composition, and Sex Hormones: Implications for Cardiovascular Risk
Singh, P., Covassin, N., Marlatt, K. L., Gadde, K. M., & Heymsfield, S. B. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210014 · Cited by 44
Testosterone therapy and cardiovascular diseases
Cittadini, A., Isidori, A. M., & Salzano, A. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab241 · Cited by 42
Algeffari, M., Jayasena, C. N., Mackeith, P., Thapar, A., Dhillo, W. S., & Oliver, N. S. (2017) · Diabetic Medicine · doi:10.1111/dme.13553 · Cited by 42
A Possible Relationship Between Testosterone and Lower Urinary Tract Symptoms in Men
Chang, I. H., Oh, S., & Kim, S. C. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.02.123 · Cited by 41
Fink, J. E., Matsumoto, M., & Tamura, Y. (2018) · Steroids · doi:10.1016/j.steroids.2018.08.002 · Cited by 42
Ho, C.-H., Yu, H.-J., Wang, C.-Y., Jaw, F.-S., Hsieh, J.-T., Liao, W.-C., Pu, Y.-S., & Liu, S.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074173 · Cited by 40
Huang, G., Pencina, K. M., Li, Z., Basaria, S., Bhasin, S., Travison, T. G., Storer, T. W., Harman, S. M., & Tsitouras, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02545 · Cited by 40
Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications
Kumar, M., Dutta, D., Anne, B., Shivaprasad, Sinha, A., Ray, S., & Chowdhury, S. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s50777 · Cited by 42
Predictive value of serum testosterone for type 2 diabetes risk assessment in men
Atlantis, E. E., Fahey, P. P., Martin, S., O’Loughlin, P. D., Taylor, A. W., Adams, R., Shi, Z., & Wittert, G. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0109-7 · Cited by 42
Hypogonadism, Type-2 Diabetes Mellitus, and Bone Health: A Narrative Review
Russo, V., Chen, R., & Armamento‐Villareal, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.607240 · Cited by 41
Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism
Almehmadi, Y., Yassin, D., & Yassin, A. A. (2015) · The Aging Male · doi:10.3109/13685538.2015.1046044 · Cited by 39
Considerations for the Diagnosis and Treatment of Testosterone Deficiency in Elderly Men
Kazi, M. H., Geraci, S. A., & Koch, C. A. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.02.022 · Cited by 39
Low Testosterone and the Association With Type 2 Diabetes
Farrell, J. A. B., Deshmukh, A., & Baghaie, A. A. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708323100 · Cited by 39
Sex differences in chronic liver disease and benign liver lesions
Cooper, K. M., Delk, M., Devuni, D., & Sarkar, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100870 · Cited by 38
Hypogonadotrophic hypogonadism in type 2 diabetes
Dandona, P., Dhindsa, S., Chaudhuri, A., Bhatia, V., & Topiwala, S. (2008) · The Aging Male · doi:10.1080/13685530802317934 · Cited by 38
Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone
Caliber, M., & Saad, F. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.04.002 · Cited by 38
Sönmez, A., Haymana, C., Bolu, E., Aydoğdu, A., Tapan, S., Serdar, M. A., Altun, B., Barçın, C., Taşlıpınar, A., Meriç, C., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0951 · Cited by 38
Effects of endocrine disorders on lipids and lipoproteins
Newman, C. B. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101667 · Cited by 37
Metabolic syndrome and sexual dysfunction
Chughtai, B. I., Lee, R. K., Te, A. E., & Kaplan, S. A. (2011) · Current Opinion in Urology · doi:10.1097/mou.0b013e32834b8681 · Cited by 37
Shao, N., Yu, X., Yu, Y.-M., Li, B., Pan, J., Wu, W.-H., Zhang, H.-J., Ma, X., Hao, M., & Kuang, H. (2018) · Andrologia · doi:10.1111/and.13039 · Cited by 39
Sarkar, M., VanWagner, L. B., Terry, J. G., Carr, J. J., Rinella, M., Schreiner, P. J., Lewis, C. E., Terrault, N., & Cohort, F. T. C. A. R. D. I. Y. A. (. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000138 · Cited by 37
Bhasin, S., & Storer, T. W. (2008) · Frontiers of hormone research · doi:10.1159/000176052 · Cited by 37
Serum testosterone levels in diabetic men with and without erectile dysfunction
Ghazi, S., Zohdy, W., Elkhiat, Y., & Shamloul, R. M. (2012) · Andrologia · doi:10.1111/j.1439-0272.2012.01292.x · Cited by 37
Is Diabetic Skeletal Fragility Associated with Microvascular Complications in Bone?
Fajardo, R. J. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0341-8 · Cited by 38
Juang, P. S., Peng, S., Allehmazedeh, K., Shah, A., Coviello, A. D., & Herbst, K. L. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12368 · Cited by 36
Janjgava, S., Zerekidze, T., Uchava, L., Giorgadze, E., & Asatiani, K. (2014) · European journal of medical research · doi:10.1186/s40001-014-0056-6 · Cited by 38
Kumari, K., Kumar, R., Memon, A., Kumari, B., Tehrim, M., Kumari, P., Shehryar, M., Islam, H., Islam, R., Khatri, M., et al. (2023) · Clinics and Practice · doi:10.3390/clinpract13020041 · Cited by 36
Sex steroids and glucose metabolism
Allan, C. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122589 · Cited by 38
Strollo, F., Strollo, G., Morè, M., Magni, P., Macchi, C., Masini, M. A., Carucci, I., Celotti, F., Ruscica, M., & Gentile, S. (2013) · The Aging Male · doi:10.3109/13685538.2013.773305 · Cited by 35
Cai, Z., Jiang, X., Pan, Y., Chen, L., Zhang, L., Zhu, K., Cai, Y., Ling, Y., Chen, F., Xu, X., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1283-0 · Cited by 35
Brooke, J. C., Walter, D., Kapoor, D., Marsh, H., Muraleedharan, V., & Jones, T. H. (2014) · Andrology · doi:10.1111/j.2047-2927.2013.00177.x · Cited by 37
Self-citationTestosterone and metabolic syndrome: The link
Ranabir, S., Kshetrimayum, A., & Reetu, K. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94248 · Cited by 38
Testosterone Replacement Therapy in Hypogonadal Men: Assessing Benefits, Risks, and Best Practices
Miner, M. M., Canty, D. J., & Shabsigh, R. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.09.1914 · Cited by 35
Oni, O. A., Dehkordi, S. H. H., Jazayeri, M., Sharma, R., Sharma, M., Masoomi, R., Sharma, R., Gupta, K., & Barua, R. S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.07.019 · Cited by 35
Hypoandrogen-metabolic syndrome: a potentially common and underdiagnosed condition in men
Gould, D. C., Kirby, R. S., & Amoroso, P. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01239.x · Cited by 35
Shoskes, D. A., Kerr, H., Askar, M. Z., Goldfarb, D. A., & Schold, J. D. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.03.102 · Cited by 35
Minnemann, T., Schubert, M., Freude, S., Hübler, D., Gouni-Berthold, I., Schumann, C. Y., Christoph, A., Oettel, M., Ernst, M. E., Mellinger, U., et al. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346421 · Cited by 35
Taylor, S. R., Meadowcraft, L., & Williamson, B. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1623 · Cited by 34
Serum free testosterone and metabolic syndrome in Japanese men
Katabami, T., Kato, H., Asahina, T., Hinohara, S., Shin, T., Kawata, T., Ohta, A., Iwamoto, T., & Tanaka, Y. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-018 · Cited by 34
Multiple Mechanisms Linking Type 2 Diabetes and Alzheimer’s Disease: Testosterone as a Modifier
Asih, P. R., Tegg, M., Sohrabi, H. R., Carruthers, M. E., Gandy, S., Saad, F., Verdile, G., Ittner, L. M., & Martins, R. N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161259 · Cited by 34
Testosterone Replacement Therapy and Mortality in Older Men
Hackett, G. I. (2015) · Drug Safety · doi:10.1007/s40264-015-0348-y · Cited by 34
Association Between Testosterone Supplementation Therapy and Thrombotic Events in Elderly Men
Ramasamy, R., Scovell, J. M., Mederos, M. A., Ren, R., Jain, L., & Lipshultz, L. I. (2015) · Urology · doi:10.1016/j.urology.2015.03.049 · Cited by 33
Sex Hormones, Insulin Resistance, and Diabetes Mellitus Among Men With or at Risk for HIV Infection
Monroe, A. K., Dobs, A. S., Xu, X., Palella, F. J., Kingsley, L., Witt, M. D., & Brown, T. T. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182278c09 · Cited by 34
McGill, J., Shoskes, D. A., & Sabanegh, E. S. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12010 · Cited by 33
Yassin, A. A., Salman, M., Alzubaidi, R. T., & Yassin, D. (2017) · The Aging Male · doi:10.1080/13685538.2017.1298584 · Cited by 33
Déficit de testosterona, síndrome metabólico y diabetes mellitus
Fernández-Miró, M., Chillarón, J. J., & Pedro‐Botet, J. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.06.020 · Cited by 33
Antonič, K. G., Antonič, B., Žuran, I., & Pfeifer, M. (2020) · The Aging Male · doi:10.1080/13685538.2020.1793132 · Cited by 33
Sakkiah, S., Wang, T., Zou, W., Wang, Y., Pan, B., Tong, W., & Hong, H. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15010025 · Cited by 35
Chodari, L., Mohammadi, M., Ghorbanzadeh, V., Dariushnejad, H., & Mohaddes, G. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.03.004 · Cited by 32
Metadata
- Authors
- Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H.
- Affiliations
- Barnsley Hospital NHS Foundation Trust (GB)
- National Health Service (GB)
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-06
- Volume
- 154
- Issue
- 6
- Pages
- 899-906
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2142908894
- Cited by
- 791
- References
- 45
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 13 · 2023: 23 · 2022: 27 · 2021: 34 · 2020: 27 · 2019: 32 · 2018: 38 · 2017: 39 · 2016: 38 · 2015: 55 · 2014: 61 · 2013: 55 · 2012: 43
- FWCI
- 36.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- testosterone replacement therapy, hypogonadism, type 2 diabetes, insulin resistance, glycemic control, visceral fat, hypercholesterolemia, dyslipidemia, HbA1c, waist circumference, cardiovascular risk
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Humans, Hypercholesterolemia, Hypogonadism, Insulin Resistance, Male, Middle Aged, Testosterone, Cross-Over Studies, Hormone Replacement Therapy, Abdominal Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
